Boehringer Ingelheim Has Two Years To Prepare CFC-Free Combivent
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA rejects a petition the firm had submitted in 2006 asking the agency exempt the COPD drug from a ban on ozone-depleting substances.
You may also be interested in...
FDA Proposes Elimination of Seven Metered-Dose Inhaler Compounds
FDA is proposing that seven drugs used in metered-dose inhalers no longer be considered essential for the treatment of asthma and chronic obstructive pulmonary disease. Without such status, the drugs will no longer be exempt from regulations banning the use of chlorofluorocarbons in aerosol containers and will have to come off the market
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
One Trial Plus Supportive Evidence Is Enough For Hospital-, Ventilator-Acquired Pneumonia Indication, Panel Says
Anti-Infective Drugs Advisory Committee members viewed one-trial as practical means of gaining efficacy data.